These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8993529)

  • 1. Lowered phosphorylation of topoisomerase I is a direct reason for reduced sensitivity of L5178Y-S cells to camptothecin.
    Staron K; Kowalska-Loth B; Szumiel I
    Ann N Y Acad Sci; 1996 Dec; 803():321-3. PubMed ID: 8993529
    [No Abstract]   [Full Text] [Related]  

  • 2. Phosphorylation of topoisomerase I in L5178Y-S cells is associated with poly(ADP-ribose) metabolism.
    Staron K; Kowalska-Loth B; Nieznanski K; Szumiel I
    Carcinogenesis; 1996 Mar; 17(3):383-7. PubMed ID: 8631120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.
    Lanza A; Tornaletti S; Stefanini M; Evans HH; Ricanati M; Astaldi Ricotti GC; Pedrini AM
    Carcinogenesis; 1993 Sep; 14(9):1759-63. PubMed ID: 8403196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of the effect of camptothecin in x-irradiated L5178Y-R and L5178Y-S cells by benzamide.
    Gradzka I; Iwaneńko T; Kruszewski M; Szumiel I; Kapiszewska M; Lange CS; Afanasjev G
    Radiat Environ Biophys; 1996 Aug; 35(3):185-91. PubMed ID: 8880961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The sensitivity to camptothecin of DNA topoisomerase I in L5178Y-S lymphoma cells.
    Staron K; Kowalska-Loth B; Szumiel I
    Carcinogenesis; 1994 Dec; 15(12):2953-5. PubMed ID: 8001262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced sensitivity to camptothecin of topoisomerase I from a L5178Y mouse lymphoma subline sensitive to X-radiation.
    Kowalska-Loth B; Staron K; Buraczewska I; Szumiel I; Kapiszewska M; Lange CS
    Biochim Biophys Acta; 1993 Feb; 1172(1-2):117-23. PubMed ID: 8382526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations of human DNA topoisomerase I at poly(ADP-ribose) binding sites: modulation of camptothecin activity by ADP-ribose polymers.
    Tesauro C; Graziani G; Arnò B; Zuccaro L; Muzi A; D'Annessa I; Santori E; Tentori L; Leonetti C; Fiorani P; Desideri A
    J Exp Clin Cancer Res; 2014 Sep; 33(1):71. PubMed ID: 25227992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Camptothecin resistance related to drug-induced down-regulation of topoisomerase I and to steps occurring after the formation of protein-linked DNA breaks.
    Murren JR; Beidler DR; Cheng YC
    Ann N Y Acad Sci; 1996 Dec; 803():74-92. PubMed ID: 8993502
    [No Abstract]   [Full Text] [Related]  

  • 9. Discrepancy between the initial DNA damage and cell survival after camptothecin treatment in two murine lymphoma L5178Y sublines.
    Gradzka I; Szumiel I
    Cell Biochem Funct; 1996 Sep; 14(3):163-71. PubMed ID: 8888569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular resistance to camptothecins.
    Pommier Y; Gupta M; Valenti M; Nieves-Neira W
    Ann N Y Acad Sci; 1996 Dec; 803():60-73. PubMed ID: 8993501
    [No Abstract]   [Full Text] [Related]  

  • 11. Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis.
    Li XG; Haluska P; Hsiang YH; Bharti AK; Kufe DW; Liu LF; Rubin EH
    Biochem Pharmacol; 1997 Apr; 53(7):1019-27. PubMed ID: 9174116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased camptothecin sensitivity of the stem-cell-like fraction of Caco2 cells correlates with an altered phosphorylation pattern of topoisomerase I.
    Roy A; Tesauro C; Frøhlich R; Hede MS; Nielsen MJ; Kjeldsen E; Bonven B; Stougaard M; Gromova I; Knudsen BR
    PLoS One; 2014; 9(6):e99628. PubMed ID: 24960044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of topoisomerase I mutations affecting both DNA cleavage and interaction with camptothecin.
    Li XG; Haluska P; Hsiang YH; Bharti A; Kufe DW; Rubin EH
    Ann N Y Acad Sci; 1996 Dec; 803():111-27. PubMed ID: 8993505
    [No Abstract]   [Full Text] [Related]  

  • 14. SF2/ASF protein inhibits camptothecin-induced DNA cleavage by human topoisomerase I.
    Kowalska-Loth B; Girstun A; Piekiełko A; Staroń K
    Eur J Biochem; 2002 Jul; 269(14):3504-10. PubMed ID: 12135490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topoisomerase I inhibitors. An overview of the camptothecin analogs.
    Burris HA; Fields SM
    Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ubiquitin, SUMO-1, and UCRP in camptothecin sensitivity and resistance.
    Desai SD; Mao Y; Sun M; Li TK; Wu J; Liu LF
    Ann N Y Acad Sci; 2000; 922():306-8. PubMed ID: 11193908
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug resistance mechanisms of topoisomerase I drugs.
    Andoh T; Okada K
    Adv Pharmacol; 1994; 29B():93-103. PubMed ID: 8996603
    [No Abstract]   [Full Text] [Related]  

  • 18. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.
    Eng WK; McCabe FL; Tan KB; Mattern MR; Hofmann GA; Woessner RD; Hertzberg RP; Johnson RK
    Mol Pharmacol; 1990 Oct; 38(4):471-80. PubMed ID: 2172765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based analysis of the effects of camptothecin on the activities of human topoisomerase I.
    Champoux JJ
    Ann N Y Acad Sci; 2000; 922():56-64. PubMed ID: 11193925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation.
    Sorensen M; Sehested M; Christensen IJ; Larsen JK; Jensen PB
    Br J Cancer; 1998 Jun; 77(12):2152-61. PubMed ID: 9649127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.